Cite
HARVARD Citation
Geng, C. et al. (n.d.). A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. American journal of hematology. 89 (11), pp. 1037-1042. [Online].